Loading...
XNAS
ATYR
Market cap56mUSD
Dec 05, Last price  
0.82USD
1D
-0.47%
1Q
-85.31%
Jan 2017
-61.68%
IPO
-95.72%
Name

aTyr Pharma Inc

Chart & Performance

D1W1MN
XNAS:ATYR chart
P/E
—
P/S
241.95
EPS
—
Div Yield, %
—
Shrs. gr., 5y
85.78%
Rev. gr., 5y
-11.05%
Revenues
235k
-33.43%
000000422,00010,455,000010,386,000353,000235,000
Net income
-64m
L+27.06%
-20,014,000-24,350,000-47,973,000-57,855,000-48,207,000-34,515,000-22,237,000-14,958,000-32,464,000-44,277,000-50,389,000-64,023,000
CFO
-69m
L+108.06%
-11,378,000-17,311,000-22,824,000-36,797,000-52,861,000-42,364,000-31,063,000-20,013,000-15,301,000-33,075,000-41,886,000-33,220,999-69,119,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
URL
https://www.atyrpharma.com/
IPO date
May 07, 2015
Employees
65
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT